{Reference Type}: Journal Article
{Title}: Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.
{Author}: Mooghali M;Mohammad A;Wallach JD;Mitchell AP;Ross JS;Ramachandran R;
{Journal}: JAMA Netw Open
{Volume}: 7
{Issue}: 5
{Year}: 2024 May 1
{Factor}: 13.353
{DOI}: 10.1001/jamanetworkopen.2024.9233
{Abstract}: This cross-sectional study evaluates the use of the US Food and Drug Administration’s Real-Time Oncology Review (RTOR) program in confirming the effectiveness of cancer drugs.